An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors

Proteasome inhibitors bortezomib, carfilzomib and ixazomib (approved by the US Food and Drug Administration [FDA]) induce remissions in patients with multiple myeloma (MM), but most patients eventually become resistant. MM and other hematologic malignancies express ubiquitous constitutive proteasome...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Adv
Päätekijät: Downey-Kopyscinski, Sondra, Daily, Ellen W., Gautier, Marc, Bhatt, Ananta, Florea, Bogdan I., Mitsiades, Constantine S., Richardson, Paul G., Driessen, Christoph, Overkleeft, Herman S., Kisselev, Alexei F.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2018
Aiheet:
Lymphoid Neoplasia
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6177641/
https://ncbi.nlm.nih.gov/pubmed/30266819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018016360
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia